Humana Inc. $HUM Shares Bought by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC boosted its stake in shares of Humana Inc. (NYSE:HUM) by 10.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 953 shares of the insurance provider’s stock after acquiring an additional 91 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Humana were worth $233,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC acquired a new position in Humana during the first quarter worth $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Humana by 16.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock worth $300,728,000 after acquiring an additional 158,528 shares during the period. Focus Partners Wealth raised its position in Humana by 104.2% during the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after acquiring an additional 3,281 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Humana by 2.4% during the first quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock worth $33,256,000 after buying an additional 2,950 shares in the last quarter. Finally, Circle Wealth Management LLC purchased a new stake in shares of Humana during the first quarter worth $425,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 3.6%

Shares of HUM opened at $280.24 on Monday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $315.35. The firm has a 50-day moving average price of $279.45 and a 200 day moving average price of $258.04. The firm has a market capitalization of $33.71 billion, a P/E ratio of 21.51, a P/E/G ratio of 1.64 and a beta of 0.42.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. During the same period in the prior year, the company posted $6.96 EPS. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. Humana’s dividend payout ratio is presently 27.17%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HUM. Wells Fargo & Company upped their target price on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a report on Tuesday, October 7th. Morgan Stanley dropped their target price on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a report on Thursday, July 31st. Evercore ISI began coverage on shares of Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price for the company. Robert W. Baird dropped their target price on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a report on Friday, July 25th. Finally, Mizuho upped their target price on shares of Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $298.83.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.